Where innovative Medical Go-To-Market Success is the rule!
Want to Learn or See More? Click here
Synergistic Marketing, founded in 1990 by Mark Lutvak, is a successful, growing and profitable sales and marketing contracting firm and consultancy. We are dedicated to serving Small Emerging businesses that own or possess Medical Technology or Medical Device IP. We support our clients with a go-to-market strategy that takes advantage of our extensive network of medical industry companies as well as our extensive list of contacts who are our Corporate Partners.
Want to Learn or See More? Click here
- October 17, 2014:
UCSF is the first medical center in the western United States to offer a miniature wireless CardioMEMS HF System implant, approved in late May by the U.S. Food and Drug Administration which enables patients heart conditions to be monitored daily in the comfort of their own home.
Once the patient returns home, heart rates and artery pressures are monitored daily by a portable electronic unit and special pillow containing an antenna. The resulting data is transmitted in real time to a secure database at the hospital or clinic for review by a physician or nurse.Full Story
- October 16, 2014:
David Soll, biology professor at the University of Iowa and corresponding author on the study, published in the journal PLOS ONE have found a gene in a soil-dwelling amoeba that functions similarly to the main tumor-fighting gene found in humans, called PTEN. The research also found a close relative of ptenA in the amoeba, which they called lpten that performs the same functions of ptenA, but to a lesser degree—a possible bench player in the amoeba's genome.
When healthy, PTEN suppresses tumor growth in humans. But the gene is prone to mutate, allowing cancerous cells to multiply and form tumors. In amoeba, researchers hypothesized that ramping up the presence of lpten could overcompensate for the mutated ptenA. If the hypothesis holds true for human cells, it could lead to a new way to treat cancer that could save many cancer patients from undergoing chemotherapy and radiation treatment for breast and other common cancers.Full Story
- October 14, 2014:
Researchers have developed a technique to jump-start the body's systems for creating blood vessels. The international team, led by scientists at the Indiana University School of Medicine, is targeting new therapies for illnesses such as peripheral artery disease, a painful leg condition caused by poor blood circulation. The disease can lead to skin problems, gangrene and sometimes amputation.
Mervin C. Yoder Jr., M.D., Richard and Pauline Klingler Professor of Pediatrics at IU reported, in Nature Biotechnology, they had developed a potential therapy through the use of patient-specific induced pluripotent stem cells for creating new blood vessels.Full Story
- October 6, 2014:
BD and CareFusion announced Sunday a definitive agreement under which BD will acquire CareFusion for $58 per share in cash and stock, or a total of $12.2 billion, to create a global leader in medication management and patient safety solutions. The combination of the two companies’ complementary product portfolios will offer integrated medication management solutions and smart devices, from drug preparation in the pharmacy, to dispensing on the hospital floor, administration to the patient, and subsequent monitoring. BD is confident in its ability to achieve identified cost synergies as it builds a dynamic organization that brings together two world class companies and offers opportunities for employees as part of a global leader.Full Story
- September 26, 2014:
NIH through a new program is awarding nearly $2.5 million to spur innovation in mobile communication technologies and software applications used in biomedical research in low- and middle-income countries (LMICs). "NIH and Fogarty have had a longstanding interest in the potential of cellphones, smartphones and mobile apps as powerful health intervention tools," said Fogarty Director Dr. Roger I. Glass. "These new mHealth awards will enhance efforts of researchers and clinicians in low-resource settings, while yielding crucial data on implementation, scale-up, and what works and what doesn't."Full Story
- September 24, 2014:
Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute alcohol-related liver failure, often a fatal diagnosis.
“A bioartificial liver could potentially sustain patients with acute liver failure until their own livers self-repair,” said Steven D. Colquhoun, MD, the surgical director of liver transplantation at Cedars-Sinai’s Comprehensive Transplant Center.Full Story